Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methotrexate intravitreal - Aldeyra Therapeutics

Next Previous
X
Search
Drug Profile

Methotrexate intravitreal - Aldeyra Therapeutics

Alternative Names: ADX 2191

Latest Information Update: 17 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard Medical School; Massachusetts Eye and Ear
  • Developer Aldeyra Therapeutics
  • Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Proliferative vitreoretinopathy; Intraocular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Intraocular lymphoma
  • Phase III Proliferative vitreoretinopathy
  • Phase II Retinitis pigmentosa

Most Recent Events

  • 01 Oct 2024 Aldeyra Therapeutics plans to initiate a phase II/III trial in Retinitis pigmentosa in 2H of 2024
  • 29 Jun 2023 Aldeyra Therapeutics plans to meet with regulatory authorities to discuss the initiation of a pivotal phase II/III trial in Retinitis pigmentosa
  • 29 Jun 2023 Efficacy and adverse events data from a phase II trial in Retinitis pigmentosa released by Aldeyra Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top